March 23, 2022 5:05pm

The cell and gene therapy sector is still trying to adjust the balancing of risk and sentiment

Pre-open indications: 8 Hits and 4 MISS

What I provide is an intelligence daily. RMi outlines a daily bell weather of “indications” about what you need to know; it’s what could happen or materialize after the opening and what might happen during the session.

The metrics say it all … just the facts; compare two (2) sessions – Tuesday versus Monday

Who else is tracking a broad grouping of cell and gene therapy equities – can you afford to not read the facts supported by real numbers?

If I have learned one thing as a former research analyst, venture and public fund investor now a journalist; it is that your life and your bank account are largely tied to your knowledge of price movements and questioning pricing targets.

 

The Dow closed DOWN -448.96 points (-1.29%); the S&P closed DOWN -55.37 points (-1.23%) while the Nasdaq closed DOWN -186.21 points (1.32%)

 

Henry’omics:

U.S. indexes lessened their positioning i.e., dropping on Wednesday as oil prices gained, renewing inflation fears.

All three (3) averages are on track to close the month more than 1% higher.

 

RegMed/Stem/Cell and Gene Therapy’s 35 covered equities’ Advance/Decline (A/D) lines: what happened …

  • Wednesday opened negative at 8 up/26 downs, 1 flat, stayed negative at the mid-day at 16/18 and 1 flat, ending with a negative close of 6/28 and 1 flat;

 

Pre-open Indications: 8 Hits < Biostage (BSTG -$0.0); SELL: Agenus (AGEN) -0.11), Bellicum Pharmaceuticals BLCM) -$0.07), Mesoblast (MESO -$0.31), uniQure NV (QURE -$0.98), Sage Therapeutics (SAGE -$1.15), Sangamo Therapeutics (SGMO -$0.34), Global Blood Therapeutics (GBT -$0.11), > 4 Miss < Pluristem (PSTI) +$0.06), Beam Therapeutics (BEAM -$4.90), Caribou Biosciences -$0.42), Fate Therapeutics -$0.96)>  

 

RegMed/Cell and Gene Therapy Earnings Scorecard Q4/21 and FY21 Results … https://www.regmedinvestors.com/articles/11628  … (FIXX) added with 30 to date

 

Key Metrics:

  • Wednesday - Sector volume was LOW with 2 of the 6-upside having higher than the 3-month average volume with LOW volume of 3 of 28-downside having higher than the 3-month average volume;

The iShares NASDAQ Biotechnology (IBB) and the SPDR S&P ETF (XBI) indicators:

  • Wednesday, the IBB was down -2.52% and the XBI was down -2.40%

The CBOE Volatility Index (VVIX: INDEX) tracked:

  • Wednesday was up +0.63 points or =2.75% at 23.45

 

Jumping with share pricing momentum (6 of 6):

  • Vericel (VCEL +$0.77 after Tuesday’s +$1.07 and Monday’s -$1.62),
  • Voyager Therapeutics (VYGR +$0.52),
  • Regenxbio (RGNX +$0.13 after Tuesday’s +$0.69),
  • Brainstorm Cell Therapeutics (BCLI +$0.10),
  • Cellectis SA (CLLS +$0.09),
  • Pluristem (PSTI +$0.06),

Hammered in today’s market (10 of 28):

  • Beam Therapeutics (BEAM -$4.90 after Tuesday’s +$2.55 and Monday’s -$3.98),
  • CRISPR Therapeutics (CRSP -$3.93 after Tuesday’s +$1.84 after Monday’s -$2.23),
  • Intellia Therapeutics (NTLA -$3.30 after Tuesday’s +$3.48 and Monday’s -$2.37),
  • Ultragenyx (RARE -$2.01 after Tuesday’s +$2.00 and Monday’s -$1.00),
  • Alnylam Pharmaceuticals (ALNY -$1.48 after Tuesday’s +$1.40 and Monday’s -$2.82),
  • Sage Therapeutics (SAGE -$1.15 after Tuesday’s +$1.15 and Monday’s -$1.09),
  • BioLife Solutions (BLFS -$1.00 after Tuesday’s -$1.64),
  • uniQure NV (QURE -$0.98 after Tuesday’s +$0.45),
  • Fate Therapeutics (FATE -$0.96),
  • Ionis Pharmaceuticals (IONS -$0.61 after Tuesday’s +$1.36 and Monday’s -$0.33),

Closing Flat:

  • Biostage (BSTG)

 

March, Q1/2022:

  • Wednesday closed negative with 6 incliners, 28 decliners and 1 flat
  • Tuesday closed positive with 31 incliners and 4 decliners
  • Monday closed negative with 2 incliners, 31 decliners and 2 flats

 

The BOTTOM LINE: Cell and gene stocks fell Wednesday to give back some gains after rising a day (Tuesday)earlier, as investors after feeling the upside and battling the sell options and risks of dramatic move to the upside after a Monday’s crash.

I am still maintaining,” Caution is in order.”

What and which go up, also slip down; it’s sector physiology as risks go both ways.

Last Friday ended on a high sector upside, Monday gave back gains and Tuesday feathered another upside move while Wednesday sold-off some equities for a quick profit.

Remember the adage, “It takes two to make a market"; that’s sellers and buyers.

I stick to my view of anticipating the risks – as my careers focus has been “warning analysis”; risk to growth now takes center stage for how long separation of sentiment lasts and how deep the oversold dive.

Q4 and end-of-year earnings are still “gamy” than even I thought.

Earnings’ reporting coming:

·         Brainstorm Cell Therapeutics (BCLI), Monday, 3/28

Who is defining the metrics for investors and keeping you notified of the sector and market fluctuations?  What I provide is a trusted source of share pricing intelligence – it’s more than opinion, I deal in the facts and numbers that back them up.

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.

Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.